Gem Aromatics Ltd
Incorporated in October 1997, Gem Aromatics Limited manufactures speciality ingredients, including essential oils, aroma chemicals, and Value-Added Derivatives in India.[1]
- Market Cap ₹ 809 Cr.
- Current Price ₹ 155
- High / Low ₹ 350 / 133
- Stock P/E 15.4
- Book Value ₹ 88.1
- Dividend Yield 0.00 %
- ROCE 22.8 %
- ROE 22.2 %
- Face Value ₹ 2.00
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 67.7 to 101 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 447 | 497 | |
| 372 | 411 | |
| Operating Profit | 76 | 86 |
| OPM % | 17% | 17% |
| 3 | 5 | |
| Interest | 6 | 7 |
| Depreciation | 6 | 7 |
| Profit before tax | 67 | 77 |
| Tax % | 26% | 26% |
| 49 | 57 | |
| EPS in Rs | 10.56 | 12.13 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 9 | 9 | 10 |
| Reserves | 218 | 275 | 450 |
| 85 | 145 | 114 | |
| 19 | 18 | 40 | |
| Total Liabilities | 331 | 447 | 614 |
| 37 | 37 | 34 | |
| CWIP | 2 | 6 | 7 |
| Investments | 1 | 1 | 99 |
| 292 | 403 | 473 | |
| Total Assets | 331 | 447 | 614 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 42 | -12 | |
| -25 | -54 | |
| -12 | 50 | |
| Net Cash Flow | 6 | -16 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 35 | 101 |
| Inventory Days | 180 | 151 |
| Days Payable | 16 | 15 |
| Cash Conversion Cycle | 199 | 236 |
| Working Capital Days | 124 | 114 |
| ROCE % | 23% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Jan - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2025.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Jan
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
8 Jan - Postal ballot to appoint Mr Shrenik K. Vora as Non-Executive Non-Independent Director; remote voting Jan 9–Feb 7, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Dec - Investor 1-on-1 meetings Dec 31, 2025 and Jan 2, 2026 with Coheron, Oculus & ABN; Q2/H1FY26 presentation public.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Dec - Investor meetings scheduled Dec 31, 2025 (Coheron Wealth) and Jan 2, 2026 (Oculus Capital & ABN Capital).
Concalls
-
Nov 2025Transcript PPT REC
Business Profile[1][2]
The company specializes in producing high-quality essential oils, aroma chemicals, and value-added derivatives. It has a strong foundation in mint- and clove-based products and growing capabilities in eucalyptus and phenol derivatives, it offers a portfolio of around 70 products across four categories. These ingredients find wide applications in oral care, cosmetics, nutraceuticals, pharmaceuticals, wellness and pain management, as well as personal care segments.